Shanghai Cell Therapy Group

CompanyChina

Shanghai Cell Therapy Group develops one asset, in phase 1 (Nicotinamide Mononucleotide in enhance immune function). Mostly supplement acting on Mitochondrial biogenesis (PGC-1α), sirtuin signalling and NAD+ metabolism; based in China.

1
Asset
Furthest stage: Phase 1; 1
Trial: 6
Signals

Pipeline

1

Nicotinamide Mononucleotide
NAD+ precursor supplement that boosts cellular NAD+ levels and supports mitochondrial metabolism
Phase 1, Supplement, Mitochondrial biogenesis (PGC-1α), Sirtuin signalling, enhance immune function, aging (Human trials)

Full company profiles: pipeline, trials, funding and people.

In the full profile

Evidence behind the mechanisms4
Trials1
Signals20
Similar companies6